RT Journal Article
SR Electronic
T1 Crohn’s disease and ulcerative colitis patient perspectives on clinical trials and participation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19000273
DO 10.1101/19000273
A1 Orna Ehrlich
A1 James Testaverde
A1 Caren Heller
A1 Stuart Daman
A1 Annick Anderson
A1 Peter D.R. Higgins
YR 2019
UL http://medrxiv.org/content/early/2019/06/25/19000273.abstract
AB Background Clinical trial recruitment is often the rate-limiting step in the development of new treatments reaching patients across all disease states. With more than 1500 currently available clinical trials for inflammatory bowel diseases (IBD) patients, it is important to understand patient perceptions of clinical trial participation to improve recruitment and retention. This study aimed to examine the specific challenges and barriers that might be reducing IBD patient enrollment and potential methods to overcome these barriers.Methods Five in-person patient focus groups were conducted from February through May 2016 using two facilitation guides. Participants self-reported a diagnosis of Crohn’s disease or ulcerative colitis.Results The five focus groups included a total of 34 participants. Participants discussed several barriers, including fears, disease severity at trial onset, potential adverse effects, time constraints, and the influence of both their primary IBD provider and support network. Methods to improve participation included better communication to prospective patients, reduced length of trial and time commitment, lower placebo rates, the option of open label extension, and support of the patient’s primary IBD provider.Conclusions This is the first study to examine patient perceptions for IBD clinical trial enrollment, including barriers to participation and methods to improve participation. Fear and misunderstanding of clinical trials, engagement with providers, limiting time demands, and limiting the impact on work and family were found to be barriers to participation. Creative solutions to these problems could lead to greater participation in trials and more rapid advancement of new therapies to clinical approval and use.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Crohn's & Colitis Foundation supported this study with funding from Biogen MA Inc. and Celgene Corporation.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.NAI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesData sharing not applicable to this article as no datasets were generated or analysed during the current study.